Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease 3 (Dan-NICAD 3)

26. januar 2021 oppdatert av: University of Aarhus

In a cohort of symptomatic patients referred to coronary computed tomography angiography (CCTA), the investigators aim is:

  1. To investigate and compare the diagnostic precision of Rubidium Positron Emission Tomography (Rb PET) and 15O-water PET (15O-water PET) in patients where CCTA does not exclude obstructive coronary artery disease (CAD) using invasive coronary angiography with fractional flow reserve (ICA-FFR) as reference standard.
  2. To study the diagnostic accuracy and prognostic value of computed tomography fractional flow reserve (CT-FFR) in patients where CCTA does not exclude obstructive CAD with ICA-FFR as reference standard.
  3. To validated a pre-test probability model including genetic and circulating biomarkers.
  4. To identify and characterize genetic risk variants and circulating biomarkers importance in developing CAD.
  5. To evaluate the bone mineral density in the hip and spine and correlate this to the degree of vascular calcification.

Studieoversikt

Detaljert beskrivelse

CCTA has become the preferred diagnostic modality for symptomatic patients with low to intermediate risk of CAD. Of the patients examined, CCTA exclude cardiovascular disease in 70-80% with an excellent negative predictive value of more than 95%. Having a low positive predictive value, however, CCTA often overestimates the severity of CAD, especially in patients with moderate to severe coronary calcification. Following CCTA, patients are hence unnecessarily tested using golden standard ICA-FFR. These ICAs often show no obstructive coronary stenosis and are therefore not followed by revascularization. The issues outlined raises the question of whether it is possible (1) to make a more precise risk stratification and consequently better selection of patients prior to CCTA and (2) to reduce the number of patients referred for unnecessary ICAs following CCTA.

In patients with suspicion of coronary stenosis detected by CCTA, current guidelines recommend verification of myocardial ischemia. Dan-NICAD 3 investigate the diagnostic accuracy of advanced non-invasive myocardial perfusion imaging tests; Rb PET and 15O-water PET. These examinations have shown a high diagnostic accuracy in symptomatic patients with high risk of ischemic heart disease. However, the diagnostic accuracy is not investigated in patients as follow-up after CCTA. In addition, microcirculation may impact the correlation between PET and ICA-FFR which this study will investigate further.

An alternative way to increase the diagnostic accuracy of CCTA and thus avoid unnecessary downstream testing using ICA is to utilize the ability to extract physiological information from the anatomical CCTA images. CT-FFR has in previous studies shown promising results. In addition, calculated estimation of microcirculatiory function is under development and this study will validated these algorithms. Furthermore, the prognostic value of CT-FFR is unknown and will be tested in the pooled cohort of Dan-NICAD 1, 2 and 3.

Obtained during ICA, quantitative flow ratio (QFR) is a novel wire-free approach for fast computation of FFR with potential to increase the global use of physiological lesion assessment. QFR is superior to traditional assessment of intermediate coronary lesions based on quantitative coronary analysis of ICA. However, disagreement between ICA-FFR and QFR has been identified in up to 20% of all measurements. QFR will be validated compared to PET and ICA-FFR.

Studietype

Observasjonsmessig

Registrering (Forventet)

1000

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Herning, Danmark, 7400
        • Rekruttering
        • Gødstrup Hospital
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

30 år til 100 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Patients with an indication for CCTA.

Beskrivelse

- Inclusion Criteria:

Patients with an indication for CCTA. Qualified patients who have signed a written informed consent form.

- Exclusion Criteria:

Demography and co-existing cardiac morbidity specific: Age below 30 years, patients having a donor heart, a mechanic heart, or mechanical heart pump, suspicion acute coronary syndrome or previous revascularization.

CCTA: Pregnant women, including women who are potentially pregnant or lactating, reduced kidney function, with an estimated glomerular filtration rate (eGFR) < 40 mL/min or allergy to X-ray contrast medium.

PET: contra-indication for adenosine (severe asthma, advanced atrioventricular block, or critical aorta stenosis).

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Cohort

Participants consenting to the study will undergo:

a1) An interview a2) Blood samples withdrawals a3) ECG a4) Non-enhanced CT a5) CCTA a6) Follow-up for > 10 years

Patients with suspicion of coronary stenosis detected by CCTA will after undergo:

b1) Rb PET b2) 15O-water PET b3) Invasive coronary angiography with 3 vessel measurement of fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microvascular resistance (IMR)

Head to head comparison with invasive FFR as reference. Adjustment for abnormal microcirculation

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Diagnostic accuracy of Rb PET and 15-O PET
Tidsramme: ICA: 4 weeks after inclusion
Head-to-head comparison using ICA-FFR as reference standard stratified for CFR
ICA: 4 weeks after inclusion

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Diagnostic accuracy of QFR vs. ICA-FFR
Tidsramme: ICA: 4 weeks after inclusion
Head-to-head comparison using ICA-FFR as reference standard
ICA: 4 weeks after inclusion
Pre-test probability model of CAD
Tidsramme: ICA: 4 weeks after inclusion
Advanced pre-test probability model of CAD included clinical information, genetic and circulating biomarkers
ICA: 4 weeks after inclusion
Diagnostic accuracy of QFR
Tidsramme: ICA: 4 weeks after inclusion
Head-to-head comparison using ICA-FFR as reference standard
ICA: 4 weeks after inclusion
Diagnostic accuracy of CT-FFR
Tidsramme: ICA: 4 weeks after inclusion
Head-to-head comparison with PET using ICA-FFR as reference standard
ICA: 4 weeks after inclusion
Effect of reduced myocardial perfusion defect on symptoms of angina pectoris
Tidsramme: Re-PET: 12 months after inclusion
12 months re-PET investigation will by used for estimation of reduction of myocardial perfusion defect size which will be correlated with symptoms of angina pectoris 3 and 12 mdr. after ICA
Re-PET: 12 months after inclusion
Prognostic value of clinical, biomarker, genetic information
Tidsramme: Follow-up: Myocardial infarction and mortality rates after 3+5+10 years
Prognotic models will be developed based on machine learning algorithms
Follow-up: Myocardial infarction and mortality rates after 3+5+10 years
Prognostic value of clinical markers, CCTA, Rb PET, 15O-water PET, CT-FFR and QFR
Tidsramme: Follow-up: Myocardial infarction and mortality rates after 3+5+10 years
Prognotic models will be developed based on machine learning algorithms
Follow-up: Myocardial infarction and mortality rates after 3+5+10 years
Predictive models of obstructive CAD
Tidsramme: ICA: 4 weeks after inclusion
Development of pre-test probability models of obstructive CAD at ICA
ICA: 4 weeks after inclusion

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Simon Winther, MD, PhD, Hospital Unit West, Herning, Denmark

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

5. januar 2021

Primær fullføring (Forventet)

5. juli 2022

Studiet fullført (Forventet)

5. januar 2023

Datoer for studieregistrering

Først innsendt

11. januar 2021

Først innsendt som oppfylte QC-kriteriene

11. januar 2021

Først lagt ut (Faktiske)

13. januar 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

29. januar 2021

Siste oppdatering sendt inn som oppfylte QC-kriteriene

26. januar 2021

Sist bekreftet

1. januar 2021

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere